FOTEMUSTIN PRI DISSEMINIROVANNOY MELANOME KOZhI


Cite item

Full Text

Abstract

Представлен обзор многочисленных исследований, посвященных использованию препарата из группы нитрозопроизводных фотемустина для лечения диссеминированной меланомы кожи (ДМК). Фотемустин обладает уникальными фармакологическими свойствами, что позволяет использовать его у пациентов с ДМК в качестве первой линии лечения в комбинированных режимах химиотерапии с высокой эффективностью. Он идеально подходит для лечения церебральных метастазов. Препарат характеризуется невысокой токсичностью, отсроченной, обратимой и предсказуемой. Фотемустин удобен в применении и идеально подходит как для стационарного, так и для амбулаторного применения.

Full Text

Restricted Access

About the authors

M. E Abramov

References

  1. Petit T, Borel C, Rixe O, et al. Complete remission seven years after treatment for metastatic malignant melanoma. Cancer 1996;77:900-02.
  2. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicentric phase II study of the nitrosourea fotemustine in 153 evaluable patient with disseminated malignant melanoma including patient with cerebral metastases. Cancer 1990;66:1873-78.
  3. Hauschild A, Avril M, Aamdal S, et al. Fotemustine versus Dacarbazine as first line treatment in disseminated malignant melanoma with or without brain metastases: A randomized phase III trial. Ann Oncol 2004;13 (Suppl. 5):157.
  4. Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol 2002;29(5):427-45.
  5. Mornex F, Thomas L, Mohr P, et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 2003; 13(1):97-103.
  6. Jacquillat C, Khayat D, Banzet P, et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemotherapy Pharmacol 1990;25:263-66.
  7. Gerson S. Modulation of human lymphocyte O6-methylguanine-DNA methyltransferase by Streptozotocin in vivo. Cancer Res 1989;49:3134-38.
  8. Lee S.M, Thatcher N, et al. In vivo depletion of 06-alkylguanine-DNA alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemother Pharmacol 1992;31:240-46.
  9. Lee S.M, Thatcher N, Marginson G.P. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral leukocytes following Dacarbazine and Fotemustine. Cancer Res 1991; 51:619-23.
  10. Avril M.F, Bonneterre J, Cupssol D, et al. Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992;28A(11): 1807-11.
  11. Avril M.F, Bonneterre J, Delaunay M, et al. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother Pharmacol 1990;27:81-84.
  12. Rixe O, Borel C, Paraiso D, et al. Fotemustine, Dacarbazine, Vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. Melanoma Res 1995;5(6):419-24.
  13. Avril M.F, Bonneterre J, Cupissol D, et al. Fotemustine plus dacarbazine for malignant melanoma. Eur J Cancer 1992;28A(11): 1807-1 1.
  14. Seeber A, Binder M, Steiner A, et al. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Eur J Cancer 1999;35(7):1163-64.
  15. Merimsky O, Inbar M, Chaitchik S. Fotemustine and DTIC combination in patients with disseminated malignant melanoma. Am J Clin Oncol 1992;15(1):84-86.
  16. Khayat D, Cour V, Bizzari J.P, et al. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. Am J Clin Oncol 1991;14(5):400-04.
  17. Pontes J.L, Lopes M, Ribeiro M, et al. Santos Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma. Eur J Cancer 2001; 37(Suppl. 6):83.
  18. Semb K.A, Aamdal S, Bohmann T, et al. Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. Melanoma Res 1998;8(6):565-72.
  19. Richard M.A, Grob J.J, Zarrour H, et al. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. Melanoma Res 1998;8(2):170-74.
  20. Daponte A, Ascierto P.A, Gravina A, et al. Italian Cooperative Oncology Group. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Cancer 2000;89(12):2630-36.
  21. Weichenthal M, Mohr P, Stephan U, et al. Fotemustine and interferon alpha2b in metastatic malignant melanoma. J Cancer Res Clin Oncol 1998;124( 1 ):55-59.
  22. Terheyden P, Becker J.C, Kampgen E, et al. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma. Melanoma Res 2000; 10(5):475-82.
  23. Egerer G, Lehnert T, Max R, et al. Pilot study of hepaticintraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol 2001;6(1):25-28.
  24. Woll E, Bedikian A, Legha S.S. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999;9(6):575-81.
  25. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15(7):2589-95.
  26. Avril M, Aamdal S, et al. Fotemustine versus Dacarbazine as first line treatment in disseminated malignant melanoma: A randomized phase III trial. J Clin Oncol 2004;22:1118-25.
  27. Tas F, Camlica H, Topuz E. Temozolomide in combination with Fotemustine in patients with metastatic melanoma. Cancer Chemother Pharmacol 2008;62(2):293-98.
  28. Comella P, Daponte A, Casaretti R, et al. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in the treatment of advanced melanoma. Eur J Cancer 1997;33(8):1326-29.
  29. De Rossi A, Rossi L, Laudisi A, et al. Focus on Fotemustine. J Exp Clin Cancer Res 2006;25(4):461-68.
  30. Egyhazi S, Margison G.P, Hansson J, et al. Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases. Eur J Cancer 1997;1:129-34.
  31. Ma S, Egyhazi S, Martenhed G, et al. Analysis of O6-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. Melanoma Res V2002;12(4):335-42.
  32. Pegg A.E, Byers T.L. Repair of DNA containing O6-alkylguanine. FASEB J 1992;6:2302-10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies